Upstate Active Clinical Trials
Study Title:S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors, Crizotinib, Savolitinibm and Sunitinib in Metastatic Papillary Renal Carcinoma
What is the purpose of the study?This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate, crizotinib, volitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Upstate Institutional Review Board (IRB) Number:921506
Patient Age Group:Adults
Principal Investigator:Sam Benjamin, MD
Where will the study take place?Upstate Cancer Center - All procedures
Oneida - All procedures
Oswego - All procedures
Who can I contact for more information?
Name: Alexandra Koulouris, BA